SCHEDULE: Deep Track Capital Discloses 5.13% Stake in Ocular Therapeutix

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a beneficial ownership of 5.13% in Ocular Therapeutix, Inc.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively beneficially own 11,234,132 shares of Ocular Therapeutix, Inc. Common Stock.
• This ownership represents 5.13% of the total class of securities outstanding.
• The calculation of the percentage is based on 218,855,497 shares, which includes 217,691,779 Common Stock outstanding as of February 2, 2026, and 1,163,718 Pre-Funded Warrants exercisable by the reporting persons.
• The Pre-Funded Warrants are subject to a 9.99% maximum exercise limitation, preventing the holder from beneficially owning in excess of this percentage after exercise.
• The reporting persons have shared voting power and shared dispositive power over all 11,234,132 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Ocular Therapeutix, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a specialized investment firm like Deep Track Capital can be interpreted as a strong endorsement of Ocular Therapeutix's value proposition and future potential.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial stake in Ocular Therapeutix, indicating confidence in the company's prospects.
• The investment includes Pre-Funded Warrants, suggesting a strategic entry point and potential for future conversion into common shares.

Risks

• The beneficial ownership includes Pre-Funded Warrants, which are subject to a 9.99% maximum exercise limitation, potentially restricting the reporting person's ability to increase their stake beyond this threshold through warrant conversion.

Future Outlook

This filing does not contain forward-looking statements or guidance from Ocular Therapeutix, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

StockSavvy.ai notes that significant institutional investments, such as this 5.13% stake by Deep Track Capital, often signal a vote of confidence in a company's long-term strategy or pipeline, particularly within the biotechnology sector where R&D success and market adoption are critical drivers. Such filings can attract attention from other institutional investors and retail traders, potentially influencing market sentiment for Ocular Therapeutix, Inc.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may instill confidence and potentially attract further investment, positively impacting share price.
• Company Management: A substantial stake by an active investor like Deep Track Capital could lead to increased scrutiny or engagement regarding corporate strategy and performance.

Key Dates

Keywords

Ocular Therapeutix, Deep Track Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Pre-Funded Warrants, Institutional Investment, Biotechnology, Healthcare